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Background: CDK9 is the catalytic subunit of the Positive Transcription Elongation Factor b (P-TEFb), which
phosphorylates the CTD of RNAPII and negative elongation factors enabling for productive elongation after
initiation. CDK9 associates with T-type cyclins and cyclin K and its activity is tightly regulated in cells at different
levels. CDK9 is also the catalytic subunit of TAK (Tat activating Kinase), essential for HIV1 replication. Because of
CDK9′s potential as a therapeutic target in AIDS, cancer, inflammation, and cardiomyophathy it is important to
understand the consequences of CDK9 inhibition. A previous gene expression profiling study performed with
human glioblastoma T98G cells in which CDK9 activity was inhibited either with a dominant negative mutant
form of CDK9 (dnCDK9) or the pharmacological inhibitor Flavopiridol unveiled striking differences in gene
expression effects. In the present report we extended these studies by (1) using both immortalized normal human
fibroblasts and primary human astrocytes, (2) eliminating potential experimental variability due to transduction
methodology and (3) also modulating CDK9 activity with siRNA.
Findings: Striking differences in the effects on gene expression resulting from the strategy used to inhibit CDK9
activity (dnCDK9 or FVP) remain even when potential variability due to viral transduction is eliminated. siRNA
mediated CDK9 knockdown in human fibroblasts and astrocytes efficiently reduced CDK9 expression and led to
potent changes in gene expression that exhibit little correlation with the effects of dnCDK9 or FVP. Interestingly,
HEXIM1 a validated CDK9 target gene, was found to be potently downregulated by dnCDK9, FVP and siCDK9, but
the cluster of genes with expression profiles similar to HEXIM1 was small. Finally, cluster analysis of all treatments
revealed higher correlation between treatments than cell type origin.
Conclusion: The nature of the strategy used to inhibit CDK9 profoundly affects the patterns of gene expression
resulting from CDK9 inhibition. These results suggest multiple variables that affect outcome, including kinetics of
inhibition, potency, off-target effects, and selectivity issues. This is particularly important when considering CDK9
as a potential target for therapeutic intervention.
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CDK9 is the catalytic subunit of the positive Transcrip-
tion Elongation Factor b (P-TEFb), which associates with
T-type cyclins (T1 and T2) and cyclin K regulatory sub-
units (reviewed in [1-3]). These complexes promote
transcriptional elongation via phosphorylation of the C-
terminal domain (CTD) of the large subunit of RNA
polymerase II (RNAPII) and subunits of the negative* Correspondence: xgrana@temple.edu
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article, unless otherwise stated.elongation factors DSIF (DRB Sensitivity Inducing Fac-
tor) and NELF (Negative Elongation factor)[3]. CDK9
preferentially triggers phosphorylation of Pro-directed
Ser/Thr sites [4]. Phosphorylation of RNAPII by CDK9
has been reported to occur preferentially on Ser-2 rather
than Ser-5 on the seven-amino acid repeats that form
the CTD [5]. However, we have previously shown that in
at least two cell lines inhibition of CDK9 activity with
flavopiridol (FVP) or a dominant negative mutant of
CDK9 results in inhibition of both Ser-2 and Ser-5 phos-
phorylation on the CTD of RNAPII [6,7]. Many genes
are regulated at the elongation rather than the initiation
phase of transcription and P-TEFb is recruited byentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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start sites of many of these promoters. CDK9 inhibition
has been studied as a potential therapeutic target for
multiple pathologies, including, AIDS, cardiac hyper-
trophy, inflammation and cancer ([8-14]). We and others
have determined the effect of inhibiting CDK9 activity in
global gene expression by different means including
pharmacological inhibitors [6,7,15,16], a dominant nega-
tive mutant of CDK9 [6] and RNA interference targeted
to various P-TEFb subunits [17-19] using a variety of
cells. Effects on gene expression have been clearly seen
in all instances, but it is unclear if the differential pat-
terns of gene expression reflect cell type and/or signal
specific differences, or alternatively the differences are
due to the kinetics of CDK9 inhibition, potency or the
potential off target effects specific to each methodology.
Off target effects may include lack of selectivity in
pharmacological approaches, anti-viral effects due to
viral transduction in dominant negative and RNA inter-
ference approaches, as well as squelching effects in both
dominant negative and RNA interference approaches.
In this study we sought to compare global changes in
gene expression resulting from inhibition of CDK9 activ-
ity by different means in hTERT immortalized normal
human fibroblasts and primary astrocytes, as well as
compare them to previous data obtained using T98G
glioblastoma cells [6].
Results and discussion
We had previously reported differential effects on gene
expression in human glioblastoma T98G cells when
CDK9 activity was either inhibited pharmacologically
with FVP or with a dominant negative form of CDK9
(dnCDK9) expressed from an adenoviral vector [6].
Changes in mRNA expression were determined via Affy-
metrix microarray analysis. The effects of FVP in mRNA
expression were consistent with global inhibition of
transcription, whereas inhibition of CDK9 activity with
dnCDK9 had more restricted and distinctive effects, with
the expression of slightly more genes being upregulated
that downregulated [6]. These data suggested that the
broader and more potent inhibitory effects of FVP in
transcription could be due to the inhibition of other
CTD kinases. This is conceivable, because although FVP
IC50 for CDK9 is 4 fold lower than for other tested
CDKs, the IC50 for several other CDKs [13,20], including
some with the ability to phosphorylate the CTD of
RNAPII has not been reported. However, it must be
considered that the differences in the mechanisms of
CDK9 inhibition, as well as the inhibition kinetics and
potency may explain at least some of the distinctive gene
expression effects. While FVP inhibits CDK9 activity
very potently and rapidly, inhibition with dnCDK9 is
much slower, depending on expression of the dominantnegative mutant and replacement of endogenous CDK9
from T-type cyclin complexes within the cell. Moreover,
since transduction of cells with adenoviruses has an ef-
fect on gene expression [21], we could not rule out that
vector effects contributed to the differences in gene ex-
pression between FVP and dnCDK9.
Effects of dnCDK9 and FVP in adenovirally transduced
human BJ-TERT fibroblasts
To extend this study, we selected a non-transformed cell
line of normal human fibroblasts immortalized with hu-
man telomerase (hTERT), designated BJ-TERT fibro-
blasts. In our hands these cells have proliferation
properties similar to those exhibited by parental non-
immortal BJ fibroblasts [22,23]. To eliminate the effects
of transduction as a cause of differential effects in gene
expression, all cells were transduced identically using the
inducible Adeno-X™ Tet-Off system from Clontech car-
rying a dnCDK9 transgene under a tetracycline repress-
ible promoter. BJ-TERT cells were transduced with the
same sets of adenoviruses (Ad-X-dnCDK9 and Ad-Tet-
off ). Tetracycline was added to the media of the control
cells (tet-DN), as well as cells to be treated with FVP
(FVP/DN/tet) to prevent expression of dnCDK9, while
cells selected to express dnCDK9 were allowed to grow
in the absence of tetracycline (DN, see methods). Under
these experimental conditions, the baseline gene expres-
sion was the same in all samples prior to inhibition of
CDK9 by different means. Forty-eight hours post-
transduction, we analyzed the effects of CDK9 inhibition
on phosphorylation of RNAPll on serine position 2 (Ser-2)
and 5 (Ser-5) using specific antibodies (Figure 1A). CDK9
is thought to phosphorylate Ser-2 during transcription
elongation, while CDK7 phosphorylates Ser-5 at initiation
[5]. However, and consistent with our previous observa-
tions using T98G cells [6], both Ser-2 and Ser-5 were
found to be clearly dephosphorylated in BJ-TERT cells
expressing dnCDK9 or treated with FVP (Figure 1A, com-
pare lanes 1–2 and 5–10 to lanes 3–4). BJ-TERT fibro-
blasts transduced in parallel in the presence of tetracycline
were treated with 300 nM FVP for the indicated last 4, 8
and 24 h prior to the 48 h collection time (under these
conditions cells remain attached to the tissue culture dish
and show no signs of overt cell death). FVP inhibited
Ser-2 and Ser-5 phosphorylation at all time points more
efficiently than dnCDK9. Consistent with its global inhibi-
tory effect on transcription, the levels of endogenous
CDK9 and, less prominently, cyclin T1 (24 h time point)
were also downregulated by the FVP treatment (Figure 1A)
and total protein concentration significantly decreased by
the 24 h time point (data not shown). We also verified the
inhibitory effects of dnCDK9 and FVP on the expression
of HEXIM1, a gene known to be modulated by P-TEFb,
which is very sensitive to CDK9 inhibition [6,24]. As
Figure 1 Effects of CDK9 inhibition on the phosphorylation of the CTD of RNAPII and the expression of genes in hTERT-immortalized
normal human fibroblasts. CDK9 activity was inhibited in BJ-TERT fibroblasts via adenoviral mediated transduction of a tetracycline-repressible
(tet) dominant negative CDK9 mutant (DN) or by pharmacological treatment with 300 nM flavopiridol (FVP). No functionally significant DN
expression occurs in the presence of tetracycline (lanes 3 to 10). FVP treated cells were also previously transduced with the same adenoviruses
and cultured in the presence of tetracycline (no DN effect) to normalize for viral effects as described in the text. All treatments were done in
triplicate and duplicate samples are shown in A and B. The other replicate performed separately but under the same conditions exhibited virtually
the same effects (not shown). Ectopic expression of dnCDK9 or treatment with FVP inhibit both RNAPII Ser-2 and Ser-5 phosphorylation. (A) and
the expression of HEXIM1 transcripts. (B) as determined by western and northern blot analysis, respectively. Coomassie Blue (A) and EtBr (B) stains
are shown for loading controls. (C) Global gene expression effects of ectopic expression of dnCDK9 or FVP treatment in BJ-TERT fibroblasts.
Normalized Affymetrix microarray data (log2 ratios, see the text in the results section) for all transcripts of triplicate samples were analyzed by
correlation uncentered, average linkage, hierarchical clustering (left heat map). Transcripts whose levels changed +/− 1 log2 in any treatment
were reclustered (middle heat map) and the heat map was magnified for clarity (right heat map). See the text in the results section for details.
Correlations are shown on the top of the arrays. A heat map legend is shown.
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regulated by both dnCDK9 and FVP. The effects of over-
expressing cyclin T1 and CDK9 were also monitored. No
major effects were noticed in the phosphorylation of the
CTD of RNAPII or the expression of HEXIM1 mRNA, as
compared to control cells infected with Ad-Cre, express-
ing the Cre recombinase.
We next performed a global gene expression profiling
of the effects of inhibiting CDK9 in BJ-TERT fibroblasts
by using Affymetrix Human Gene 1.0 ST DNA arrays
and total RNAs from the samples described above in
triplicate. These arrays contain probes representing
28,869 different genes. RNAs were labeled, hybridized to
microarrays and scanned as described in [6]. Raw tran-
script intensity data were normalized and the expression
value log2 ratio for each gene was computed between its
treatment and corresponding control sample (tet/DN
was the control for DN and the FVP/DN/Tet treat-
ments; Ad-Cre (CR) was the control for Ad-T1/K9 (T1/K9); and ctr is the ratio of the two control treatments
tet/DN vs. Ad-Cre (CR)). Principal component analysis
demonstrates that all biological replicates cluster to-
gether (Additional file 1: Figure S1). We represented the
average gene expression value between replicates as the
average log2 ratio. Next, hierarchical cluster analysis was
performed with the log2 ratios and visualized using by
Java Tree View (Figure 1C). Gene array ratios for the
three FVP treatments clustered together (correlation:
0.76-0.91), but exhibited much lower correlation with
the dnCDK9 gene array ratios (correlation: 0.44). If
only the probe sets that change two fold or more (log2
ratios ≤ −1 or ≥1) with at least one treatment are consid-
ered, this correlation increases slightly (0.50)(Figure 1C,
right clusters). Interestingly, ectopic expression of
P-TEFb subunits (cyclin T1 and CDK9) resulted in the
marked upregulation of a small subset of genes, with
mostly no effect on genes dramatically upregulated/
downregulated by FVP or dnCDK9. Of note, the small
Garriga and Graña BMC Research Notes 2014, 7:301 Page 4 of 10
http://www.biomedcentral.com/1756-0500/7/301subset of genes upregulated were highly enriched with
interferon response genes, which could indicate that
in virally transduced cells P-TEFb activity is limiting
(Additional file 2: Figure S2). As expected, very little dif-
ference was observed in the expression profile of both
control cell treatments: cells transduced with Ad-X-
dnCDK9/Ad-Tet in the presence of tetracycline versus
Ad-Cre (Figure 1C, ctr (tet/DN vs. CR), right array in all
clusters).
Analysis of the probe sets that change approximately
two fold or more (log2 ratios ≤ −1 or ≥1) upon dnCDK9
expression showed that 93 probe sets were downregu-
lated and 32 were upregulated (Figure 2). The highest
downregulation corresponded to HEXIM1 (log2 =−1.72043),
confirming the sensitivity of HEXIM1 to CDK9 inhibition.
As expected, FVP also potently inhibited HEXIM1 expres-
sion (log2 = −1.72494 to −3.22926). The highest probe set
intensity in the dnCDK9 array was CDK9, an obvious ex-
pected result due to the ectopic expression of dnCDK9, as
the probe set does not discriminate between dnCDK9 and
endogenous CDK9. Of note, FVP inhibited the expression
of endogenous CDK9. The correlation between the FVP
arrays was 0.95 for the 4 and 8 h treatments and 0.84 with
the 24 h treatment. It was also clear that the increase/de-
crease in gene expression with FVP was time dependent.
The correlation between the FVP and dnCDK9 arrays was
0.57, noticeably higher than we had seen in our previous
study using T98G cells [6]. The lowest log2 ratio was −1.7
and the highest was 2.2, while the expression change range
for FVP at 24 h was much higher (−5.4 to 4.2). Therefore,
one cannot conclude that the effects of dnCDK9 are more
or less potent than any of the FVP treatments for this set
of genes but rather different.
Global effect on gene expression with loss of CDK9 function
via siRNA
The observation that many of the genes more sensitive
to dnCDK9 or FVP treatment are different suggest that
one or both methods lack selectivity or have off target
effects. For instance, FVP may inhibit other CDKs with
roles in transcription in addition to CDK9, even at the
concentrations used in this study. One could also envi-
sion dnCDK9 having additional effects unrelated to
CDK9 inhibition resulting from squelching P-TEFb part-
ners. Alternatively, the differences could be explained by
the difference in kinetics of inhibition of FVP compared
to dnCDK9. FVP acts very rapidly and potently, while
inhibition by dnCDK9 occurs slowly, depending on ex-
pression and replacement of active complexes by in-
active ones. In view of these results, we decided to
broaden our study by reducing CDK9 expression via
siRNA. This is a priori a very specific and selective
method, as no other RNA sequences are targeted and,
thus, other RNAPII CDKs should not be directlyaffected. BJ-TERT fibroblasts were transfected twice
within 24 h with two independent siRNAs (103 and 104)
and collected 72 h after the first transfection. We next
determined the effect of each siRNA and their combin-
ation on CDK9 levels. Both 103 and 104 siRNAs effi-
ciently knocked-down CDK9 mRNA and protein
(Figure 3A), with little additional downregulation when
both siRNAs were used in combination. As expected
scramble siRNAs had no effect on CDK9 levels. How-
ever, in contrast to FVP and dnCDK9 treatments
(Figure 1A), phosphorylation of Ser-2 and Ser-5 of the
CTD of RNAPII were not visibly affected by either
siCDK9 or their combination (Figure 3A). The effects
of knocking-down CDK9 in global gene expression in
BJ-TERT fibroblasts were determined using Affymetrix
Human Gene 1.0 ST DNA arrays similarly as described
for dnCDK9 and FVP treated cells. Cells were trans-
fected in triplicate with each siCDK9 or combination or
in duplicate with scramble siRNA. Cells were collected
72 h later to generate RNA probes (see Methods). About
650 probe sets exhibited changes in gene expression
equal or larger than two fold (log2 ratios ≤ −1 or ≥1). A
cluster analysis of genes that changed two fold or more
with siCDK9 or dnCDK9 is shown in Figure 3B. The
correlation between siCDK9 treatments was high (0.86-
0.95). Both the 103 and 104 siRNAs exhibit some unique
set of genes that were more potently affected, with the
combination appearing to be additive for those genes.
However, for genes that were commonly downregulated
or upregulated by both siRNA separately, the combin-
ation mostly lacked additive effects (Figure 3B, side grey
bars). This may reflect that both siRNAs knocked-down
CDK9 to similar levels even when used in combination,
as the total siRNA concentration was the same in all
transfections. Surprisingly clustering analysis also re-
vealed major differences between the effect of the siR-
NAs and dnCDK9 (correlation 0.15). For instance a large
set of genes upregulated by dnCDK9 are not affected by
either siRNA (bottom large cluster in the array). Similarly,
the top of the array shows several genes potently downreg-
ulated by dnCDK9 that show minimal downregulation by
siRNA. In addition, most of the genes upregulated by
either 103, 104 or the combination of both are either not
affected or downregulated by dnCDK9. While there is
more agreement within the genes downregulated by the
siRNAs, the overall comparison exhibits little similarity.
The effect of these siRNAs were also determined in
primary human astrocytes. Cells were transfected in du-
plicate with siRNAs targeting CDK9 (103 and 104),
scramble or mock transfected and cells were harvested
72 h later. As with BJ-TERT fibroblasts, 103 and 104,
but not scramble knocked down CDK9 mRNA and pro-
tein (Figure 4A). RNA was prepared from transfected
and untransfected cells for microarray analysis and data
Figure 2 (See legend on next page.)
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Figure 2 Effects of FVP treatment on genes modulated by dnCDK9 in hTERT-immortalized normal human fibroblasts. Affymetrix
microarray expression ratios for transcripts changing +/−1 log2 with ectopic expression of dnCDK9 were clustered with the corresponding values
of the FVP treatments using hierarchical clustering analysis (correlation uncentered, average linkage). Correlations among treatments are shown
on the top dendogram. Gene clusters are shown on the left of the heat map. A heat map legend is shown.
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this experiment to determine whether any of the effects
observed in siRNA transfected cells could be due to ex-
perimental manipulation. We observed that transfection
had significant effects in the expression of interferon re-
sponse genes as well as other genes. Transfection with
one of the siRNAs directed to CDK9 (104) had add-
itional effects on the expression of these genes, which
were dramatically upregulated, but were not upregu-
lated with the other siRNA directed to CDK9 (103).
Elimination of those genes in clustering analysis allows
focusing in the potentially regulated genes, defined
as those affected by transfection with both 103 and
104, but not scr, as compared to untransfected cells
(Figure 4B).Figure 3 Very limited correlation among genes modulated by siCDK9
results in reduced cyclin T1 expression, but does not affect RNAPII phospho
as loading control. NT indicates untransfected cells and scr indicates scram
changed a +/−1 log2 ratio or more with siCDK9 (103 and/or 104 vs. scr) or
Cluster 3.0 (correlation uncentered, average linkage)(~650 transcripts are sh
legend is shown.Finally, we combined all microarray data from this
study and our previously published data using T98G
cells [6] to perform hierarchical cluster analysis. Interest-
ingly, this analysis shows that gene arrays cluster by
treatment rather than cell type or transformation status
(Figure 5A). Specifically, the FVP treatments of T98G
and BJ-TERT fibroblasts clustered together, as did siRNA
transfected cells or cells expressing dnCDK9. These data
show that the type of treatment induces clear signatures
shared in across cell types that are more prominent than
cell type specific signatures that could result from inhib-
ition of CDK9 by any methodology (Figure 5B).
In summary, it is clear that the strategy selected to in-
hibit CDK9 activity in cells contributes to the changes in
gene expression observed and, thus, caution needs to beand dnCDK9 in hTERT immortalized NHF. (A) Knockdown of CDK9
rylation noticeably. The Coomassie Blue stained membrane is shown
ble siRNA. (B) log2 expression ratios for transcripts which levels
dnCDK9 (DN vs. tet/DN) expression were hierarchically clustered using
own). The correlation among arrays is show on top. A heat map
Figure 4 Effect of CDK9 knockdown on gene expression in primary astrocytes. (A) Knockdown of CDK9 results in markedly reduced CDK9
expression (siRNA experiments were done in triplicate as shown). A representative portion of the Coomassie Blue stained PDVF membrane is
shown as loading control. NT indicates untransfected cells and scr indicates scramble siRNA. (B) log2 expression ratios for transcripts which levels
changed a +/−log2 ratio or more with siCDK9 after elimination of genes which expression was altered nonspecifically by transfection of scr siRNA
(see text) were clustered (correlation uncentered, average linkage). Correlation distances are shown on the top dendogram. A heat map legend
is shown.
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comparing results obtained using different strategies
(Figure 5B). Because pharmacologic inhibitors such as
FVP act rapidly (within minutes of treatment), the ob-
served effects in gene expression are acute and more
likely to be direct if the pharmacologic inhibitor is se-
lective in cells. In our hands, FVP inhibits phosphoryl-
ation of RNAPII on both Ser-2 and Ser-5 (Figure 1),
even when used for shorter periods of time [7]. Also,
using lower concentrations of FVP in cells did not result
in significantly greater selectivity [7]. So, it cannot be
ruled out that the potency of FVP is in part due to
inhibition of other CTD kinases with roles in transcrip-
tional elongation and responsible for Ser-5 phosphoryl-
ation. On the other hand, it is also conceivable that
CDK9 phosphorylates both Ser-2 and Ser-5 in cells, and
this is consistent with the results obtained with
dnCDK9, which inhibits phosphorylation of both. Sur-
prisingly, we did not observe major changes in the phos-
phorylation state of both Ser-2 and Ser-5 upon CDK9
knockdown, which might suggest that in the absence of
CDK9 other CDKs may act redundantly to maintain
overall CTD phosphorylation in cells. It is anticipated
that development of more selective pharmacologic in-
hibitors of CDK9 will help resolve the open questions in
the future.These observations are significant because CDK9 is
being evaluated as a therapeutic target for a number of
pathologies and the efficacy of treatments targeting
CDK9 would be predicted to be highly variable depend-
ing on the approach used to inhibit CDK9 activity.
Methods
Cell culture
BJ-TERT fibroblasts are normal human BJ fibroblasts
immortalized with human Telomerase Reserve Tran-
scriptase (hTERT) [25]. BJ-TERT fibroblasts were grown
in Dulbecco’s Modification of Eagle’s Medium (DMEM)
(Cellgro) supplemented with 10% Fetal Bovine Serum
(FBS) (Sigma) and antibiotics at 37°C in 5% CO2. Normal
human astrocytes (NHA) were purchased from Lonza and
grown in astrocyte basal media (ABM™) plus growth fac-
tors (Lonza) at 37°C and 5% CO2 following manufacturer’s
directions. NHA have a limited life-span, but can be ex-
panded up to five passages.
Cell treatments
CDK9 was pharmacologically inhibited by adding Flavo-
piridol (FVP) to the medium to a final concentration of
300 nM. FVP was dissolved in DMSO to generate a
10 mM stock and then diluted in PBS to 100 μM and
added to the medium. Control cells were treated with
Figure 5 Hierarchical Cluster analysis of al treatments. (A) Genes with +/−1 log2 ratios for treatments described in this study and [6] were
clustered as described in the text and previous figures. Cell treatments are indicated on top. T indicates T98G cells, A indicates astrocytes, BJ
indicates BJ-TERT fibroblasts. FVP treatments are indicated by F4, F8 or F24. Correlation distances are shown on the top of the arrays. A heat map
legend is shown. (B) Schematic representation of the three strategies used to inhibit CDK9 activity, their mechanism, speed and potential off
target effects.
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dissolved in PBS. FVP treated cells were preinfected with
Ad-T-dnCDK9 plus Adeno-X™ Tet-Off™ adenoviruses in
the presence of tetracycline (tet/DN) to eliminate viral
transduction as a variable in the comparison to dnCDK9
expressing cells (transduced with Ad-T-dnCDK9 plus
Adeno-X™ Tet-Off™ in the absence of tetracycline (DN)).
BJ-TERT fibroblasts were infected with Ad-T-dnCDK9
plus Adeno-X™ Tet-Off™ adenoviruses (dn) in the pres-
ence or absence of tetracycline (tet) essentially as previ-
ously described [6] and then treated with FVP for 8, 4
and 24 h. Double stranded siRNAs were obtained from
Ambion and had the following sense sequences: 103, 5′-
GGUGCUGAUGGAAAACGAGtt-3′ and 104, 5′-GGA-
GAAUUUUACUGUGUUUtg-3′. The scrambled siRNA,
Scr, 5′- AAUUCUCCGAACGUGUCACGU-3′ was pur-
chased from Qiagen. BJ-TERT fibroblasts (0.5 × 106)
were seeded in 10 cm plates 14 h prior to transfection.
SiRNAs were transfected with Dharmafect using manu-
facturer-established protocols. The Dharmafect/siRNA/
antibiotic free medium mix was incubated for 20 min
at room temperature and added to cells re-fed with
fresh antibiotic free medium. NHA (1 × 106) were
transfected with 50 nM siRNA in the presence of 15 μL
Lipofectamine RNAimax (Life Technologies) in serumfree media (Optimem, Life Technologies). Media was
changed 6 hours later and cells were collected to process
for analysis 72 hours post-transfection.Protein and RNA analyses
Cells were lysed with ice-cold lysis buffer (50 mM Tris–
HCl (pH 7.4), 5 mM EDTA, 250 mM NaCl, 50 mM NaF,
0.1 mM Na3VO4, 0.1% Triton X-100, 2 mM PMSF, 4 μg/ml
aprotinin, 10 μg/ml leupeptin, and 40 μg/ml pepstanin).
Protein concentration was determined using the
BioRad protein reagent and BSA to generate a
standard curve, with all protein sample replicates
reading in the linear range. Proteins were resolved by
8% polyacrylamide/SDS gel electrophoresis, and trans-
ferred to a polyvinylidene difluoride (PVDF) mem-
brane in 10 mM CAPS/10% methanol buffer (pH 11).
ECL Western blot analyses were performed as de-
scribed previously [6] using the following antibodies:
Anti-RNAPII (A300-653A), anti-Ser-2 (A300-654A),
and anti-Ser-5 (A300-655A) rabbit polyclonal anti-
bodies were obtained from Bethyl.
Total RNA was isolated from cells using QIAshredder
and Rneasy Mini Kit from Qiagen. Northern Blots were
performed as previously described [23].
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hierarchical cluster analysis, and visualization
Global analysis of gene expression was performed using
Affymetrix Human Gene 1.0 ST microarrays, which con-
tains probe for 28,869 non-redundant transcripts. RNA
was labeled and hybridized to microarrays at the Univer-
sity of Pennsylvania Microarray Facility (U. Penn MF)
following manufacturer directions. Microarray intensity
values were normalized using the Affymetrix Expression
Console Software. The average of log2 ratios was calcu-
lated to represent average gene expression levels among
replicate arrays. Hierarchical cluster analysis was per-
formed using Cluster version 3.0 software with average
linkage [26] and visualized with Java TreeView, version
1.0.13 as in [6].
Availability of supporting data
Microarray expression data will be deposited in the GEO
database upon manuscript acceptance.
Additional files
Additional file 1: Figure S1. Principal component analysis shows that
all biological replicates cluster together. Principal component analysis was
performed with normalized data for all treatments described in Figure 1.
Biological replicates of the same treatment are colored, as shown in the
color legend on the right.
Additional file 2: Figure S2. Ectopic expression of P-TEFb subunits
(cyclin T1 and CDK9) resulted in the marked upregulation of a small subset
of genes highly enriched with interferon response genes. Ingenuity Pathway
Analysis (IPA) was performed with the set of genes upregulated in BJ-TERT
cells ectopically expressing cyclin T1 and CDK9 as compared to cells
transduced with the Ad-Cre control virus. Genes involved in cell-immediate
immune response and humoral response are highly enriched (A). IPA
Network analysis of the upregulated genes in BJ-Tert fibroblasts ectopically
expressing Cyclin T1 and CDK9 identified the interferon network, which
shows upregulation of multiple interferon response genes.
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